XML 41 R26.htm IDEA: XBRL DOCUMENT v3.25.4
Restructuring Expenses
 12 Months Ended
Dec. 31, 2025
Restructuring and Related Activities [Abstract]  
Restructuring Expenses Restructuring Expenses
During 2023, due to challenging industry dynamics and macroeconomic conditions, the Company underwent several expense containment measures such as a reduction of its headcount across many of its functions and a reduction of its real estate footprint. During the year ended December 31, 2023, the restructuring initiatives incurred $15.5 million of employee severance costs and related expenses, net of reversals. Refer to Note 13, Lessee Leases for information regarding the Company’s restructuring activities for the reduction of its real estate footprint and optimization of certain leased facilities.
On April 26, 2024, the Company’s management committed to the wind down of the Company’s Medimat Robotic Dispensing System (“RDS”) product line, subject to local law and statutory works council consultation requirements. During the year ended December 31, 2024, the Company incurred approximately $6.6 million of employee severance costs and other expenses related to the RDS product line wind down, net of immaterial reversals of previously recognized restructuring expenses. The Company also incurred $5.4 million of inventory write-down charges during the year ended December 31, 2024 related to the RDS product line wind down that were recorded to cost of revenues in the Company’s Consolidated Statements of Operations. Further, during the fourth quarter of 2025, the Company incurred additional charges related to the wind down of the Company’s RDS product line. During the year ended December 31, 2025, the Company incurred approximately $3.9 million of employee severance costs and other expenses in connection with this initiative.
During the third quarter of 2025, the Company underwent a restructuring initiative within the EnlivenHealth business in order to gain operational efficiency and synergy, and adapt to the recent industry dynamics within the retail pharmacy space. During the year ended December 31, 2025, the Company incurred approximately $2.6 million of employee severance and other related expenses in connection with this initiative.
As of December 31, 2025, the unpaid balance related to these restructuring plans was $3.9 million.
The following table summarizes the total employee-related restructuring expense, net of reversals:
Year Ended December 31,
202520242023
(In thousands)
Cost of product and service revenues$4,601 $4,504 $3,089 
Research and development937 419 3,829 
Selling, general, and administrative967 230 8,621 
Total restructuring expenses, net of reversals$6,505 $5,153 $15,539